Revenue $6.26B, up 5.5% on a year earlier. Diluted EPS $1.23 against $0.77.
| Q2 FY26 | Q1 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|---|
| Revenue | $6.26B | $5.95B | $5.94B | +5.5% |
| Operating income | $1.13B | $1.34B | $760.00M | +48.3% |
| Net income | $870.00M | $1.03B | $555.00M | +56.8% |
| Diluted EPS | $1.23 | $1.45 | $0.77 | |
| Operating cash flow | $1.53B | $1.32B | $1.34B | +14.6% |
| Capital expenditures | -$269.00M | -$237.00M | -$248.00M | |
| Free cash flow | $1.26B | $1.08B | $1.09B | +16.1% |
| Q2 FY26 | Q2 FY25 | Year over year | |
|---|---|---|---|
| Revenue Growth | 5.5% | 3.5% | |
| Diagnostics Core sales growth non-GAAP | 2% | 2% | |
| Diagnostics total sales growth GAAP | 7% | 2% | |
| Life Sciences Core sales growth non-GAAP | 5.5% | -2.5% | |
| Life Sciences total sales growth GAAP | 5.5% | 0.5% | |
| Biotechnology total sales growth GAAP | 4% | 8% | |
| Core sales growth - Biotechnology | 2.5% | 6% | |
| Core sales growth - Total Company | 3% | 1.5% |
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “Danaher (DHR) Q2 FY26 earnings: results and KPIs”, stockatlas.com/companies/DHR/earnings/2026-q2/, data as of 3 November 2026. Links to this page are welcome.
